← SynDRA
BMS-214662
SynDRA canonical compound SYN0005339 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
| Primary target(s) | FNTA | FNTB |
| Mechanism of action | farnesyltransferase inhibitor |
All known targets
Mechanisms of action (all sources)
- farnesyltransferase inhibitor
- Modulator
Cross-references
Synonyms
- BMS214662
- BMV
- (3R)-3-benzyl-1-(1H-imidazol-5-ylmethyl)-4-thiophen-2-ylsulfonyl-3,5-dihydro-2H-1,4-benzodiazepine-7-carbonitrile
- (R)-1-((1H-imidazol-5-yl)methyl)-3-benzyl-4-(thiophen-2-ylsulfonyl)-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine-7-carbonitrile
- 3-BENZYL-1-(1H-IMIDAZOL-4-YLMETHYL)-4-(THIEN-2-YLSULFONYL)-2,3,4,5-TETRAHYDRO-1H-1,4-BENZODIAZEPINE-7-CARBONITRILE
- 7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine
- L2U9GFD244
- CHEBI:167655
- RefChem:120710
- DTXCID5095751
- FTI BMS 214662
- NSC710086
- UNII-L2U9GFD244
- OLCWFLWEHWLBTO-HSZRJFAPSA-N
- SCHEMBL94663
- SCHEMBL134853
- GTPL8026
- orb1710238
- SCHEMBL29454371
- C25H23N5O2S2
- VHA98741
- BDBM50092365
- EX-A14312
- MFCD09955166
- BMS 214662 [WHO-DD]
- AKOS040732621
- CS-6471
- NCGC00509886-04
- HY-16111
- MS-29107
- NS00069582
- G13661
- T10567
- BVM
- bms-214662 hydrochloride
- C25H24ClN5O2S2
- UNII-2ZRT8VWQ9J
Look up BMS-214662 in the interactive SynDRA portal →